vs
Side-by-side financial comparison of AleAnna, Inc. (ANNA) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
AleAnna, Inc. is the larger business by last-quarter revenue ($9.1M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). AleAnna, Inc. runs the higher net margin — 2.8% vs -60.3%, a 63.2% gap on every dollar of revenue.
Anna University is a public state university located in Chennai, Tamil Nadu, India. The main campus is in Guindy. It was originally established on 4 September 1978 and is named after C. N. Annadurai, former Chief Minister of Tamil Nadu.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
ANNA vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $9.1M |
| Net Profit | $258.1K | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 2.4% | -51.1% |
| Net Margin | 2.8% | -60.3% |
| Revenue YoY | — | -49.9% |
| Net Profit YoY | 102.7% | -184.8% |
| EPS (diluted) | $0.00 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $9.1M | ||
| Q3 25 | $11.2M | $17.9M | ||
| Q2 25 | $4.0M | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q4 23 | — | $10.5M |
| Q4 25 | $258.1K | $-5.5M | ||
| Q3 25 | $5.3M | $2.4M | ||
| Q2 25 | $644.7K | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q4 23 | — | $-6.0M |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
| Q4 25 | 2.4% | -51.1% | ||
| Q3 25 | 51.0% | 11.9% | ||
| Q2 25 | 14.5% | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q4 23 | — | -53.5% |
| Q4 25 | 2.8% | -60.3% | ||
| Q3 25 | 47.4% | 13.2% | ||
| Q2 25 | 16.0% | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q4 23 | — | -57.6% |
| Q4 25 | $0.00 | $-0.06 | ||
| Q3 25 | $0.08 | $0.03 | ||
| Q2 25 | $0.01 | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q4 23 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.8M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.7M | $48.2M |
| Total Assets | $101.3M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $14.7M | ||
| Q3 25 | $31.2M | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q4 23 | — | $23.6M |
| Q4 25 | $58.7M | $48.2M | ||
| Q3 25 | $58.3M | $52.9M | ||
| Q2 25 | $52.3M | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q4 23 | — | $33.6M |
| Q4 25 | $101.3M | $82.3M | ||
| Q3 25 | $100.1M | $82.3M | ||
| Q2 25 | $89.9M | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q4 23 | — | $84.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | 14.51× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $2.0M | ||
| Q3 25 | $9.0M | $-3.7M | ||
| Q2 25 | $-700.0K | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q4 23 | — | $3.6M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q4 23 | — | $3.3M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q4 23 | — | 31.9% |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | — | 2.4% |
| Q4 25 | 14.51× | — | ||
| Q3 25 | 1.69× | -1.58× | ||
| Q2 25 | -1.09× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANNA
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
